A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment

References

• Hille A, Schmidberger H, Hermann RM, Christiansen H, Saile B, Pradier O, et al. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories in the prevention of acute radiation proctitis in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1488–93
   PubMed Web of Science ®Google Scholar
• Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1997; 43: 727–34
   Web of Science ®Google Scholar
• Michalski JM, Purdy JA, Winter K, Roach M, III, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391–402
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Franklin CI, Dear KB, Hamilton CC, Poulsen M, Joseph DJ, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol 1997; 45: 117–23
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 3–11
   PubMed Web of Science ®Google Scholar
• Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999; 53: 37–44
   PubMed Web of Science ®Google Scholar
• Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001; 59: 81–5
   PubMed Web of Science ®Google Scholar
• Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004; 39: 1113–8
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind C. TNM classification of malignant tumours5th ed. Wiley-Liss, New York/Toronto 1997; 170–3
   Google Scholar
• Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13–47
   PubMed Web of Science ®Google Scholar
• Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. Int J Radiat Oncol Biol Phys 2002; 54: 686–97
   PubMed Web of Science ®Google Scholar
• Hille A, Töws N, Schmidberger H, Hess CF. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal tissue exposure: a potential for increasing the benefit/risk ratio. Strahlenther Onkol 2005; 181: 789–95
   PubMed Web of Science ®Google Scholar
• Wachter S, Gerstner N, Dorner D, Goldner G, Colotto A, Wambersie A, et al. The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose-volume histograms during treatment course of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 91–100
   PubMed Web of Science ®Google Scholar
• Gerstner N, Wachter S, Dorner D, Goldner G, Colotto A, Potter R. Significance of a rectal balloon as internal immobilization device in conformal radiotherapy of prostatic carcinoma. Strahlenther Onkol 1999; 175: 232–8
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Manola J, Loffredo M, Lopes L, Nissen K, O'Farrell DA, et al. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 2001; 51: 1431–6
   PubMed Web of Science ®Google Scholar
• Hille A, Schmidberger H, Töws N, Weiss E, Vorwerk H, Hess CF. The impact of varying volumes in rectal balloons on rectal dose sparing in conformal radiation therapy of prostate cancer: a prospective three-dimensional analysis. Strahlenther Onkol 2005; 181: 709–16
   PubMed Web of Science ®Google Scholar
• Herbert SH, Curran WJ, Jr, Solin LJ, Stafford PM, Lanciano RM, Hanks GE. Decreasing gastrointestinal morbidity with the use of small bowel contrast during treatment planning for pelvic irradiation. Int J Radiat Oncol Biol Phys 1991; 20: 835–42
   PubMed Web of Science ®Google Scholar
• Koelbl O, Richter S, Flentje M. Influence of patient positioning on dose-volume histogram and normal tissue complication probability for small bowel and bladder in patients receiving pelvic irradiation: a prospective study using a 3D planning system and a radiobiological model. Int J Radiat Oncol Biol Phys 1999; 45: 1193–8
   PubMed Web of Science ®Google Scholar
• Shanahan TG, Mehta MP, Bertelrud KL, Buchler DA, Frank LE, Gehring MA, et al. Minimization of small bowel volume within treatment fields utilizing customized “belly boards”. Int J Radiat Oncol Biol Phys 1990; 19: 469–76
   PubMed Web of Science ®Google Scholar
• International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. International Commission on Radiation Units and Measurements, Washington, DC, 1993.
   Google Scholar
• Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1111–7
   PubMed Web of Science ®Google Scholar
• Sedgwick DM, Howard GC, Ferguson A. Pathogenesis of acute radiation injury to the rectum. A prospective study in patients. Int J Colorectal Dis 1994; 9: 23–30
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39: 1017–20
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997; 50: 113–23
   PubMedGoogle Scholar
• Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002; 14: 1
   PubMed Web of Science ®Google Scholar
• Sugi KO, Saitoh I, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel: comparison with other neutrophil derived proteins. Am J Gastroenterol 1996; 91: 927–34
   PubMed Web of Science ®Google Scholar
• Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994; 27: 259–64
   PubMed Web of Science ®Google Scholar